Family Office Of America (FOFA) Cash from Operations Growth (1y) (2022 - 2026)
Family Office Of America (FOFA) Cash from Operations Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 185.96% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 122.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 16.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Family Office Of America | 27.22 Mn | 26.88 Mn | 783,126.00 | 1,066.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,066.05% |
| Dec 31, 2025 | -386.74% |
| Sep 30, 2025 | -5.35% |
| Jun 30, 2025 | -117.09% |
| Mar 31, 2025 | -97.00% |
| Dec 31, 2024 | -313.87% |
| Sep 30, 2024 | 27.98% |
| Jun 30, 2024 | -424.04% |
| Mar 31, 2024 | 77.94% |
| Dec 31, 2023 | 92.16% |
| Sep 30, 2023 | 84.91% |
| Jun 30, 2023 | 104.95% |
| Mar 31, 2023 | 58.59% |
| Dec 31, 2022 | 41.87% |
| Sep 30, 2022 | 56.89% |